XBI $151.13 (+0.8%) 📈
COVID:
$KNSA (-0.2%) - Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
$RDHL (+0.1%) - RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
PIPELINE:
$VYGR (+3%) - Voyager Therapeutics Provides Update On NBIb-1817 (VY-AADC) Gene Therapy Program
$SPPI (-3%) - Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA
$BCRX (-8.5%) - BioCryst Provides Update on Galidesivir Program
$NKTR (+0.4%) - Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
$OCUL (+5%) - Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
$RYTM (-4.5%) - Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
FINANCIAL:
$RGNX (+6%) - REGENXBIO ANNOUNCES AGREEMENT TO MONETIZE PORTION OF ZOLGENSMA® ROYALTIES FOR $200 MILLION
Comentarios